16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, Ventripoint's vendor-agnostic technology delivers MRI-level accuracy from standard echocardiograms. The alliance will fund and place four VMS+ units, signaling commercial validation in a rapidly growing AI cardiology market projected to reach $14.2 billion by the mid-2030s.

06/16/2026, 9:11 AM • Benzinga

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement environment where hospitals now demand economic proof alongside clinical accuracy for AI cardiac imaging solutions.

05/19/2026, 8:55 AM • Benzinga

Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

Hospital networks are increasingly adopting AI-enhanced cardiac imaging technologies to reduce costs and improve patient outcomes. The AI medical imaging market is projected to reach nearly $20 billion by 2033, with echocardiography expected to grow to $2.64 billion by 2030. Key players including VentriPoint Diagnostics, Butterfly Network, Tempus AI, RadNet, and GE HealthCare are expanding their deployments across healthcare systems, with several reporting strong revenue growth and positive financial metrics.

03/03/2026, 12:19 PM • Benzinga

Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare are advancing portable, AI-powered diagnostic solutions that deliver hospital-grade precision at the bedside, reducing facility overhead while improving patient outcomes.

01/16/2026, 11:56 AM • Benzinga

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback

The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.

09/18/2025, 3:08 PM • Benzinga

Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

The global AI in healthcare market is projected to reach nearly $700 billion by 2034, growing at 38.5% annually. Companies are developing advanced AI diagnostic technologies targeting areas like diabetic retinopathy, cardiac screening, and chronic disease management, with increasing FDA approvals and commercial potential.

08/12/2025, 11:09 AM • Benzinga

Butterfly Q2 Margin Climbs to 63%

Butterfly Network reported Q2 2025 results with 9% revenue growth, record 63.7% gross margin, and narrowed losses. The company revised full-year revenue guidance lower and is focusing on AI-driven software and international expansion.

08/05/2025, 2:19 PM • The Motley Fool